Polycystic ovary syndrome (PCOS)
Endocrine · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
The commonest endocrine disorder of reproductive-age women, defined by a combination of ovulatory dysfunction, clinical/biochemical hyperandrogenism and polycystic ovarian morphology. It is a lifelong metabolic condition — manage the presenting concern (cycles, hirsutism, fertility) and the long-term cardiometabolic risk together.
Red flags
- Refer to endocrinology/gynaecology for diagnostic uncertainty or marked/rapidly progressive hyperandrogenism (exclude an androgen-secreting tumour), to fertility services for anovulatory subfertility, and for persistent abnormal bleeding needing endometrial assessment
Assessment
Investigations
- Total/free testosterone and free androgen index; exclude mimics — 17-OH-progesterone (non-classical CAH), prolactin, TSH, and cortisol/overnight dexamethasone if Cushingoid
- Pelvic ultrasound (not needed if other two criteria met in adults)
- Screen metabolically: fasting glucose/HbA1c or OGTT and lipids
Management
- Lifestyle and weight loss first-line
- Cycle regulation/endometrial protection and hirsutism: combined oral contraceptive ± anti-androgen (spironolactone)
- Metabolic: metformin for insulin resistance/impaired glucose;
- GLP-1 agonists for obesity
- Fertility: letrozole (first-line ovulation induction) ± metformin, then gonadotrophins/IVF; cosmetic measures for hirsutism
Disposition
Refer to endocrinology/gynaecology for diagnostic uncertainty or marked/rapidly progressive hyperandrogenism (exclude an androgen-secreting tumour), to fertility services for anovulatory subfertility, and for persistent abnormal bleeding needing endometrial assessment.
Complications & pitfalls
- Type 2 diabetes and gestational diabetes, dyslipidaemia and cardiovascular risk, endometrial hyperplasia/carcinoma from unopposed oestrogen, subfertility, obstructive sleep apnoea, NAFLD, and anxiety/depression
Exam pearls
- Letrozole, not clomifene, is now first-line for ovulation induction in PCOS — and in women with irregular cycles, never leave the endometrium unopposed: a progestin or combined pill every few months prevents hyperplasia.
- Monitoring & follow-up: Periodic glucose/HbA1c and lipids, blood pressure and weight; ensure at least a withdrawal bleed every 3–4 months (or a progestin/COC) to protect the endometrium; screen for mood disorders and sleep apnoea.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.